. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2013 Jan 26;11(6):604–e44. doi: 10.1016/j.cgh.2012.12.039

Table 2.

Outcomes of radioembolization in Hepatocellular Carcinoma

	Salem et al⁴⁴	Hilgard et al⁴⁵	Sangro et al⁴⁶	Salem et al⁴⁰	Mazzaferro et al⁴¹
Purpose	Assess clinical outcomes of patients treated with Y90	Assess clinical outcomes of patients treated with Y90 in Europe	Evaluate prognostic factors of survival after Y90 in European patients	Compare the effectiveness of Y90 vs. cTACE	Provide a prospective assessment of safety and efficacy for Y90 treatment of patients with intermediate and advanced disease
Patients	291	108	325	Y90: 123 TACE: 122	52
Response rate	WHO: 42% EASL:57%	EASL: 40%	-	Y90: 49% TACE: 36%	WHO: 40% EASL: 40%
TTP (months)	7.9	10	-	Y90: 13.3 TACE: 8.4	11
Survival (months)	Child-Pugh A:17.2 Child-Pugh B:7.7	16.4	BCLC A: 24.4 BCLC B: 16.9 BCLC C: 10.0	Y90:20.5 TACE: 17.4	15

Abbreviations: BCLC: Barcelona Clinic Liver Cancer; EASL: European Association for the Study of the Liver; RECIST: Response Evaluation Criteria in Solid Tumors; TACE: transarterial chemoembolization; TTP: Time-to-progression; WHO: World Health Organization